Affimed (NASDAQ:AFMD) Shares Pass Below 50 Day Moving Average – Time to Sell?

Affimed (NASDAQ:AFMD) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.42 and traded as low as $1.31. Affimed shares last traded at $1.32, with a volume of 278,795 shares traded.

Analysts Set New Price Targets

A number of brokerages recently commented on AFMD. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Affimed in a research report on Tuesday, December 10th. Stifel Nicolaus dropped their price target on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. Wells Fargo & Company reduced their price objective on Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research report on Tuesday, November 19th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $13.50.

Affimed Trading Down 9.8 %

The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.93 and a current ratio of 1.93. The business’s fifty day moving average price is $2.38 and its two-hundred day moving average price is $3.57.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in AFMD. Choreo LLC acquired a new position in Affimed during the second quarter valued at approximately $54,000. Point72 Asset Management L.P. lifted its stake in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after buying an additional 15,108 shares during the last quarter. Intellectus Partners LLC boosted its holdings in shares of Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after buying an additional 10,250 shares during the period. Jane Street Group LLC acquired a new position in Affimed in the 3rd quarter valued at $44,000. Finally, FMR LLC raised its holdings in Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. 30.82% of the stock is owned by institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.